Compare AbbVie Inc (ABBV) vs Axon Enterprise Inc (AXON) Price & Performance

AbbVie IncTrade

Axon Enterprise IncTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs Axon Enterprise Inc — how do they compare? AbbVie Inc trades at $248.33 (market cap $441.94B), while Axon Enterprise Inc trades at $629 (market cap $51.69B). The key difference: AbbVie Inc is far larger — about 8.5× Axon Enterprise Inc's market cap, and AbbVie Inc pays a 2.77% dividend while Axon Enterprise Inc pays none. Which is the better fit depends on your goals.

	ABBV	AXON
Market Cap	$441.94B	$51.69B
Sector	Health	Technology
52-Week High	$263.58	$791.62
52-Week Low	$197.38	$345.94
Enterprise Value	$506.19B	$52.83B
Dividend Yield	2.77%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.

Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.

Axon Enterprise Inc

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ABBV

Fidelity Dividend ETF's payout is safe but not ideal for steady income due to variable quarterly dividends.24/7 Wall Street · 23 hours agoNeutral Two Dividend Aristocrats outperformed the market while two lagged; three new picks show promising dividend growth.24/7 Wall Street · 2 days agoNeutral Healthcare sector leads S&P 500 gains over 3 months with key pharma stocks showing strong innovation and income potential.24/7 Wall Street · 2 days agoBullish View details →

AXON

AXON raises FY2026 guidance amid strong AI-driven hardware/software growth but stock is overbought at high valuation.Seeking Alpha · 5 hours agoBullish Axon shares jump 6% after strong Q2 earnings and raised 2026 revenue outlook24/7 Wall Street · 21 hours agoBullish View details →

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

About Axon Enterprise Inc

Axon develops technology and weapons for law enforcement and military use. Its ecosystem includes TASER devices, body cameras, and Evidence.com, a cloud-based platform for digital evidence management.